Aurinia Pharmaceuticals Dirección
Dirección controles de criterios 1/4
El CEO de Aurinia Pharmaceuticals es Peter Greenleaf , nombrado en Apr 2019, tiene una permanencia de 5.58 años. compensación anual total es $10.57M, compuesta por 7.8% salario y 92.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.22% de las acciones de la empresa, por valor de $2.76M. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 1.3 años, respectivamente.
Información clave
Peter Greenleaf
Chief Executive Officer (CEO)
US$10.6m
Compensación total
| Porcentaje del salario del CEO | 7.8% |
| Permanencia del CEO | 5.6yrs |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 4.5yrs |
| Promedio de permanencia en la Junta Directiva | 1.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Nov 08Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Sep 06
Aurinia Pharmaceuticals Appears Undervalued
Jul 05We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
May 24Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
May 02Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$23m |
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$11m | US$823k | -US$78m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$97m |
| Dec 31 2022 | US$9m | US$791k | -US$108m |
| Sep 30 2022 | n/a | n/a | -US$115m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$168m |
| Dec 31 2021 | US$1m | US$724k | -US$181m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$148m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$11m | US$673k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$129m |
| Jun 30 2020 | n/a | n/a | -US$110m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$5m | US$438k | -US$88m |
Compensación vs. Mercado: La compensación total de Peter($USD10.57M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.54M).
Compensación vs. Ingresos: La compensación de Peter ha aumentado mientras la empresa no es rentable.
CEO
Peter Greenleaf (54 yo)
5.6yrs
Permanencia
US$10,573,359
Compensación
Mr. Peter S. Greenleaf, M.B.A., is Director at NVN Liquidation Inc. He serves as Director at ValenzaBio, Inc. since August 2022. He has been Chief Executive Officer and Director of Aurinia Pharmaceuticals...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$10.57m | 0.22% $ 2.8m | |
| Chief Financial Officer | 4.6yrs | US$3.98m | 0.078% $ 993.5k | |
| Chief Operations Officer | no data | US$4.56m | 0.11% $ 1.3m | |
| Executive Vice President of General Counsel | 4yrs | US$3.60m | 0.055% $ 694.3k | |
| Head of the Corporate Communications & Investor Relations | no data | sin datos | sin datos | |
| Chief Business Officer | 4.4yrs | US$702.00k | sin datos | |
| Senior Vice President of Global Regulatory Affairs | no data | sin datos | sin datos | |
| Chief Medical Officer | no data | sin datos | 0.078% $ 987.5k | |
| Senior Vice President of Manufacturing & Supply Chain | no data | sin datos | sin datos | |
| Vice President of Investor Relation | no data | sin datos | sin datos |
4.5yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AUPH se considera experimentado (4.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$10.57m | 0.22% $ 2.8m | |
| Chairman | less than a year | sin datos | sin datos | |
| Independent Director | 5yrs | US$267.28k | 0.010% $ 130.4k | |
| Director | no data | sin datos | sin datos | |
| Independent Director | 1.3yrs | US$361.51k | 0.0093% $ 118.4k | |
| Independent Director | 1.3yrs | US$359.41k | 0.0089% $ 112.3k | |
| Independent Non-Executive Director | 9.5yrs | US$249.92k | 0.031% $ 393.0k |
1.3yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de AUPH no se considera experimentada (1.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.